Summary
We investigated whether the cytokines produced in activated microglia in the substantia nigra (SN) and putamen in sporadic Parkinson’s disease (PD) are neuroprotective or neurotoxic. In autopsy brains of PD, the number of MHC class II (CR3/43)-positive activated microglia, which were also ICAM-1 (CD 54)-, LFA-1 (CD 11a)-, TNF-alpha-, and IL-6-positive, increased in the SN and putamen during progress of PD. At the early stage activated microglia were mainly associated with tyrosine hydroxylase (TH)-positive neurites in the putamen, and at the advanced stage with damaged TH-positive neurons in the SN. The activated microglia in PD were observed not only in the nigro-striatal region, but also in various brain regions such as the hippocampus and cerebral cortex. We examined the distribution of activated microglia and the expression of cytokines and neurotrophins in the hippocampus of PD and Lewy body disease (LBD). The levels of IL-6 and TNF-alpha mRNAs increased both in PD and LBD, but those of BDNF mRNA and protein drastically decreased specifically in LBD, in which neuronal loss was observed not only in the nigrostriatum but also in the hippocampus. The results suggest activated microglia in the hippocampus to be probably neuroprotective in PD, but those to be neurotoxic in LBD. As an evidence supporting this hypothesis, two subsets of microglia were isolated from mouse brain by cell sorting: one subset with high production of reactive oxygen species (ROS) and the other with no production of ROS. When co-cultured with neuronal cells, one microglia clone with high ROS production was neurotoxic, but another clone with no ROS production neuroprotective. On the other hand, Sawada with coworkers found that a neuroprotective microglial clone in a culture experiment converted to a toxic microglial clone by transduction of the HIV-1 Nef protein with increasing NADPH oxidase activity. Taken together, all these results suggest that activated microglia may change in vivo from neuroprotective to neurotoxic subtsets as degeneration of dopamine neurons in the SN progresses in PD. We conclude that the cytokines from activated microglia in the SN and putamen may be initially neuroprotective, but may later become neurotoxic during the progress of PD.
Toxic change of activated microglia may also occur in Alzheimer’s disease and other neurodegenerative diseases in which inflammatory process is found.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Foley P, Riederer P (1999) Pathogenesis and preclinical course of Parkinson’s disease. J Neural Transm [Suppl] 56: 31–74
Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp Neurol 193: 279–290
Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evans GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and a final effector in the apoptotic cell death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci USA 97: 2875–2880
Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 44(Suppl): S115–S120
Hirsch EC, Hunot S, Faucheux B, Agid Y, Mizuno Y, Mochizuki WG, Tatton N, Olanow WC (1999) Dopaminergic neurons degenerate by apoptosis in Parkinson’s disease. Mov Disord 14: 383–385
Hirsch EC (2002) Inflammatory changes in Parkinson’s disease. In: Mizuno Y, Fischer A, Hanin I (eds) Mapping the progress of Alzheimer’s and Parkinson’s disease. Kluwer Akademic/Plenum Publishers, New York, pp 259–263
Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106: 518–526
Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2005) Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol 109: 141–150
Jellinger KA (2000) Cell death machanism in Parkinson’s disease. J Neural Transm 107: 1–29
Kosaka K (2002) Lewy body disease. Neuropathol 20(Suppl): 73–78
McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s disease and Alzheimer’s disease brain. Neurology 38: 1285–1291
McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer’s and other neurodegenerative diseases. Brain Res Rev 21: 195–218
Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammation process in Parkinson’s disease. Neuroscience 95: 425–432
Mizuno Y (2005) Progress in familial Parkinson’s disease. Parkinsonism and Related Disorders 11(Suppl 2): 54–54 (Abstract, 16th International Congress on Parkinson’s Disease and Related Disorders, Berlin, June 5–9, 2005)
Mogi M, Nagatsu T (2000) Neurotrophins and cytokines in Parkinson’s disease. Adv Neurol 80: 135–139
Nagatsu T, Mogi M, Ichinose H, Togari A, Riederer P (1999) Cytokines in Parkinson’s disease. Neuro Sci News 2: 88–90
Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Cytokines in Parkinson’s disease. J Neural Transm [Suppl 58]: 143–151
Nagatsu T (2002) Parkinson’s disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm 109: 731–745
Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharmac Design 11: 999–1016
Sarder AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuro Report 7: 910–912
Vilhardt F, Plastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E, Trono D, Krause K-H (2002) The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 277: 42136–42143
Youdim MBH, Riederer P (1997) Understanding Parkinson’s disease. Sci Am: 82–89
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag
About this paper
Cite this paper
Sawada, M., Imamura, K., Nagatsu, T. (2006). Role of cytokines in inflammatory process in Parkinson’s disease. In: Riederer, P., Reichmann, H., Youdim, M.B.H., Gerlach, M. (eds) Parkinson’s Disease and Related Disorders. Journal of Neural Transmission. Supplementa, vol 70. Springer, Vienna . https://doi.org/10.1007/978-3-211-45295-0_57
Download citation
DOI: https://doi.org/10.1007/978-3-211-45295-0_57
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-28927-3
Online ISBN: 978-3-211-45295-0
eBook Packages: MedicineMedicine (R0)